tetano
Editor, Senior Moderator
Antiviral Res. 2012 Dec 26. pii: S0166-3542(12)00301-4. doi: 10.1016/j.antiviral.2012.12.021. [Epub ahead of print]
Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection.
Tutykhina IL, Sedova ES, Gribova IY, Ivanova TI, Vasilev LA, Rutovskaya MV, Lysenko AA, Shmarov MM, Logunov DY, Naroditsky BS, Tillib SV, Gintsburg AL.
Source
Gamaleya Research Institute for Epidemiology and Microbiology, 18, Gamaleya Street, Moscow 123098, Russia.
Abstract
One effective method for the prevention and treatment of influenza infection is passive immunization. In our study, we examined the feasibility of creating an antibody-based preparation with a prolonged protective effect against influenza virus. Single-domain antibodies (sdAbs) specific for influenza virus hemagglutinin were generated. Experiments in mouse models showed 100% survivability for both intranasal sdAbs administration 24 hours prior to influenza challenge and 24 hours after infection. sdAb-gene delivery by an adenoviral vector led to gene expression for up to 14 days. Protection by a recombinant adenovirus containing the sdAb gene was observed in cases of administration prior to influenza infection (14 d - 24 h). We also demonstrated that the single administration of a combined preparation containing sdAb DNA and protein expanded the protection time window from 14 d prior to 48 h after influenza infection. This approach and the application of a broad-spectrum sdAbs will allow the development of efficient drugs for the prevention and treatment of viral infections produced by pandemic virus variants and other infections.
Copyright ? 2012. Published by Elsevier B.V.
PMID:
23274786
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23274786
Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection.
Tutykhina IL, Sedova ES, Gribova IY, Ivanova TI, Vasilev LA, Rutovskaya MV, Lysenko AA, Shmarov MM, Logunov DY, Naroditsky BS, Tillib SV, Gintsburg AL.
Source
Gamaleya Research Institute for Epidemiology and Microbiology, 18, Gamaleya Street, Moscow 123098, Russia.
Abstract
One effective method for the prevention and treatment of influenza infection is passive immunization. In our study, we examined the feasibility of creating an antibody-based preparation with a prolonged protective effect against influenza virus. Single-domain antibodies (sdAbs) specific for influenza virus hemagglutinin were generated. Experiments in mouse models showed 100% survivability for both intranasal sdAbs administration 24 hours prior to influenza challenge and 24 hours after infection. sdAb-gene delivery by an adenoviral vector led to gene expression for up to 14 days. Protection by a recombinant adenovirus containing the sdAb gene was observed in cases of administration prior to influenza infection (14 d - 24 h). We also demonstrated that the single administration of a combined preparation containing sdAb DNA and protein expanded the protection time window from 14 d prior to 48 h after influenza infection. This approach and the application of a broad-spectrum sdAbs will allow the development of efficient drugs for the prevention and treatment of viral infections produced by pandemic virus variants and other infections.
Copyright ? 2012. Published by Elsevier B.V.
PMID:
23274786
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23274786